Title:
ANTI-MCT1 ANTIBODIES AND USES THEREOF
Document Type and Number:
Japanese Patent JP2022160650
Kind Code:
A
Abstract:
To provide antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, as well as fusion proteins, and compositions containing such an antibody and antigen-binding fragment thereof and a fusion protein.SOLUTION: Such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions in vitro and/or in vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions thereof. Optionally these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions thereof are used in therapeutic regimens that further include administration of other therapeutic agents, e.g., mitochondrial inhibitors and/or biguanides or small molecule MCT1 inhibitors.SELECTED DRAWING: Figure 1
More Like This:
Inventors:
Jay Rothstein
Catherine Carrière
Sergei Serejin
Philip Gobeille
Grace Quijon Lee
Kimberly P. Shigenaka
Marcia Gordon
Kim Kuon
Wang Yong
Rafael di Levi
Jordan Kay One
Los Chambers
David Francis Tucker
Blood A Scrench
Catherine Carrière
Sergei Serejin
Philip Gobeille
Grace Quijon Lee
Kimberly P. Shigenaka
Marcia Gordon
Kim Kuon
Wang Yong
Rafael di Levi
Jordan Kay One
Los Chambers
David Francis Tucker
Blood A Scrench
Application Number:
JP2022127690A
Publication Date:
October 19, 2022
Filing Date:
August 10, 2022
Export Citation:
Assignee:
IMMUNEXT,INC.
International Classes:
C12N15/13; A61K39/395; A61P1/04; A61P3/00; A61P7/00; A61P13/12; A61P17/00; A61P17/06; A61P25/00; A61P29/00; A61P35/00; A61P37/02; A61P37/06; A61P37/08; C07K16/28; C07K16/30; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63; C12P21/08
Domestic Patent References:
| JP2021509822A | 2021-04-08 |
Foreign References:
| WO2016063037A1 | 2016-04-28 |
Other References:
EXPERIMENTAL EYE RESEARCH, vol. 153, JPN6021036112, 2016, pages 170 - 177, ISSN: 0005109212
NATURE CHEMICAL BIOLOGY, vol. 1, no. 7, JPN7021003788, 2005, pages 371 - 376, ISSN: 0005109213
BIOCHEMICAL J., vol. 320, JPN6021036114, 1996, pages 817 - 824, ISSN: 0005109214
NATURE CHEMICAL BIOLOGY, vol. 1, no. 7, JPN7021003788, 2005, pages 371 - 376, ISSN: 0005109213
BIOCHEMICAL J., vol. 320, JPN6021036114, 1996, pages 817 - 824, ISSN: 0005109214
Attorney, Agent or Firm:
Yamato Kento
Shinagawa
Wu Yingyan
Nobuhiko Akiyama
Wataru Sato
Shinagawa
Wu Yingyan
Nobuhiko Akiyama
Wataru Sato
Previous Patent: Optical transmission subassemblies and optical modules
Next Patent: Control architecture and method for blood treatment system
Next Patent: Control architecture and method for blood treatment system